Slide 1: Introduction to Imprimis Pharmaceuticals: 2014 Strategic Plan
INTRODUCTION TO IMPRIMIS PHARMACEUTICALS 2014 STRATEGIC PLAN MARK L. BAUM, CEO MARCH 2014
Slide 2: Safe Harbor
imprimis SAFE HARBOR This presentation contains express “forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. if underlyi
Slide 3: imprimis
imprimis
Slide 4: Imprimis mission today
imprimis To deliver customized and other novel To navigate the realities of the current healthcare medicines to physicians and patients economy and solve unmet patient needs through TODAY at accessible prices. ‘the development and commercialization of proprietary sterile and topical drug formulation
Slide 5: Risk and reward
RISK —> ‘e 8 REWARD — >
Slide 6: Efficient Innovation
agente EFFICIENT INNOVATION Clinical » Pursue IP protection for eet unique and proven ® ldea () e @ compounded formulations » Conduct comprehensive review methodology (ARM) Support investigator- initiated studies through grants to leading physician groups COMMERCIALIZE » State pharmacy laws and Drug
Slide 7: Innovative Solutions
INNOVATIVE SOLUTIONS ‘= z= Tiamcinolone Ace? re oxi \oxifloxacin HC! ((5h)mgimts Steele! (15/1)mg/m Steril! Superior technology allows for an elegant injectable solution for a large unmet physician and patient need.
Slide 8: Proprietary Ophthalmic Formulations
impr mis PROPRIETARY OPHTHALMIC FORMULATIONS GobDropless.com Patent Pending Sterile Injectable Formulations* For Pharmacy Compounding Our Formulations © Invented by Ophthalmologists and Pharmacists © Use patent pending technology that uniquely allow for the combination of drugs @ A single cost effec
Slide 9: 2014 Strategic Goals
niga 2014 STRATEGIC GOALS ¢ Launch ophthalmology division ¢ Launch dermatology and urology products ° Execute compounding pharmacy facilities strategy * Scale business to establish national footprint Near, medium and long term catalysts as our team executes our strategy
Slide 10: 1H 2014 Ophthalmology Launch
imprimis 1H 2014 OPHTHALMOLOGY LAUNCH CATARACT MARKET 22 million cataract surgeries globally in 2013 and nearly 3.6M in the US Major compliance and cost issues that physicians and patients struggle with Physicians report that in 90-95% of their cataract surgeries, they eliminate the use of post-oper
Slide 11: Key Competitive Advantages
Imprimiis KEY COMPETITIVE ADVANTAGES ATTRACTIVE BUSINESS MODEL + Lowers drug development costs + Increases the speed and efficiency we can bring products to market + Preserves profit margins for shareholders INNOVATIVE PATH TO MARKET + Patent-pending drug formulations and technologies prescribed by
Slide 12: Condensed Balance Sheet
CONDENSED BALANCE SHEET imprim ASSETS At Bepjember: 30, Current Assets Cash and short term investments $ 16,877,683 Other assets 525,609 TOTAL ASSETS $ 17,403,292 LIABILITIES AND STOCKHOLDERS EQUITY Accounts payable and other accruals $ 1,058,545 TOTAL LIABILITIES 1,058,545 Stockholder’s Equity Comm
Slide 13: imprimis
imprimis
Slide 14: Questions?
QUESTIONS? Imprimis PHARMACEUTICALS
Slide 15: Appendix
APPENDIX Imprimis PHARMACEUTICALS
Slide 16: Compounding Pharmacies Primer
COMPOUNDING PHARMACIES PRIMER impri + Compounding pharmacies work with physicians to develop individualized medications, such as alternative dosage strengths or unique dosage forms + Compounding pharmacies have been historically regulated primarily by state boards of pharmacy, but in November 2013 t
Slide 17: Imprimis Summary
Imprimis SUMMARY » Own, make and distribute proprietary compounded drug formulations + Strategic partnership with the largest compounding organization in the world » We own formulations in ophthalmology, wound management and urology » Commercial launch slated for 1H 2014 in ophthalmology » Unique ma